ALVO (alvotech.com) Market Value to Book Value Ratio

Official company branding of Alvotech S.A. (ALVO)

The financial stability of Alvotech (ALVO) is constrained by payment volatility, as profits are tied to court rulings and regulatory verdicts. However, the launch of commercial sales creates a powerful cash foundation, transforming the portfolio into a steady cash generator. This price chart illustrating value trends, where the indicator stands at -8.45, complements the profile of the biosimilar developer, which is actively displacing competitors through patent wars and global distribution.

ALVO Alvotech Biopharmaceuticals: Market Value to Book Value in the range 04/28/2023 - 10/27/2026
Original product of Alvotech Corp

This indicator separates fundamental business value from speculative noise by measuring the multiple of the market price to the company's net assets. For Alvotech (ALVO), whose model is based on deep R&D and strategic alliances with pharma behemoths, the price-to-book ratio serves as a precise detector of overvalued quotes relative to the actual value of intellectual property and production capacities.

Main competitors

Market Value to Book Value Ratio HLN|KVUE (kenvue.com) - Market-to-Book Ratio|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|liquidia.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Galapagos (GLPG)|ANIP: Market Value to Book Value|MNKD (MannKind Corp.) - Market Value to Book Value Ratio|Amphastar Corp (AMPH) - Market Cap to Net Assets Ratio|PCRX (Pacira BioSciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ars-pharma.com (SPRY)|Theravance Biopharma, Inc. (TBPH) - Market Cap to Net Assets Ratio|Market Value to Book Value AQST (Aquestive Therapeutics Inc)|SCPH: Market Value to Book Value Ratio|TECX - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tonix Pharmaceuticals TNXP|SXTC - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio eupraxiapharma.com EPRX|BioHarvest Sciences, Inc. (BHST) - Market Value to Book Value|Market Capitalization to Book Value Ratio EXOZ (Invizyne Technologies, Inc.)|Market-to-Book Ratio ORMP|Entera Bio Ltd. (ENTX) - Market Value to Book Value Ratio|Market Value to Book Value ipatherapeutics.com (HYFT)|Market Capitalization to Book Value Ratio ABVC (ABVC BioPharma, Inc.)|Cumberland Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|QNTM - Market Value to Book Value Ratio|FibroGen Corporation (FGEN) - Market Value to Book Value Ratio|Telomir Pharmaceuticals (TELO) - Market Cap to Net Assets Ratio|RANI (Rani Therapeutics Holdings, Inc.) - Market Value to Book Value Ratio|Market Value to Book Value Ratio SNYR (Synergy CHC Corp.)|Market-to-Book Ratio Rallybio Corp. (RLYB)|Market Cap to Net Assets Ratio Lexaria Bioscience|Market Cap to Book Value Multiple Pulmatrix Corporation (PULM)|PTHL: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Aptorum Group Ltd APM|LYRA: Market Capitalization to Book Value Ratio|IBO - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio tnfpharma.com TNFA|cbdMD (YCBD) - Market Value to Book Value|PRFX (PainReform Ltd.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio CYTO|Market Value to Book Value Ratio Lipella Pharmaceuticals, Inc. (LIPO)|Market Value to Book Value Ratio OptiNose Inc OPTN|Market Cap to Net Assets Ratio Pieris PIRS|Procaps Group Corp - Market Value to Book Value Ratio|PTPI (Petros Pharmaceuticals) - Market Value to Book Value Ratio|QLI: Market-to-Book Ratio|Market Value to Book Value Ratio ACELYRIN (SLRN)|TFF Pharmaceuticals Inc. (TFFP) - Market Capitalization to Net Assets